From Patent Reform to Public Health Risk? Analysing India's 2024 Patent Amendment Rules

Understanding India's Patent Landscape Before 2024

India's patent system has long balanced innovation incentives with public welfare, particularly in pharmaceuticals. Under Section 3(d) of the Patents Act, 1970, incremental innovations lacking enhanced therapeutic efficacy are barred to prevent evergreening—extending monopolies on minor drug modifications. Pre-grant oppositions under Section 25(1) allowed third parties to challenge applications, while annual Form 27 statements ensured patents were "worked" in India, enabling compulsory licensing (CL) under Section 84 if unmet. This framework positioned India as the 'pharmacy of the world,' supplying 20% of global generics and saving $500 billion in healthcare costs since 2000.

Key Provisions of the Patent (Amendment) Rules, 2024

Notified on March 15, 2024, the rules streamline procedures amid a backlog of 80,000+ applications. Examination requests shortened to 31 months from 48, aligning with EPO timelines. Divisional applications (Section 16) now permit multiple filings post-grant if voluntary. Foreign filing disclosures (Rule 12) shift to one-time post-first examination report. Crucially, pre-grant oppositions (Rule 55) introduce prima facie maintainability checks, fees (₹4,000 individuals, ₹20,000 entities), and expedited refusals. Form 27 (Rule 131) moves to triennial simplified declarations sans revenue details.

Overhaul of Pre-Grant Opposition Mechanism

Rule 55's changes impose a Controller-led filter: oppositions dismissed without applicant notice if lacking prima facie merit. Opponents get one-month responses; hearings optional. Fees deter civil society, previously filing ~1% oppositions effectively blocking weak pharma claims. Oppositions dropped to 0.55% in recent years, yet vital for scrutiny—e.g., rejecting 70% pharma challenges pre-grant.

Risks of Facilitating Evergreening in Pharmaceuticals

Evergreening delays generics via secondary patents on salts, formulations. Reduced foreign prosecution data access hampers spotting global rejections, easing Section 3(d) evasion. Nirma University analysis warns diluted oppositions enable frivolous grants, prolonging monopolies. Pharma filings ~10% of 110,000 annual applications; grants surged 149% in 2023 per WIPI 2025.

Simplified Patent Working Statements and CL Challenges

Form 27's triennial checkbox format obscures non-working, imports not counting as 'working.' This delays CL under Section 84 (reasonable needs unmet after 3 years). Post-2012 Natco-Bayer Sorafenib CL slashed prices 97%; no new grants since, but applications rejected due to data gaps. Critics decry transparency loss, aiding stockpiling without local production.

Photo by A Chosen Soul on Unsplash

Case Studies: TB and Hepatitis Drugs Under Threat

• Bedaquiline (J&J): TB survivors' opposition rejected secondary patent 2023, enabling generics halving prices. New fees/filter risk future blocks.
• Sofosbuvir/Velpatasvir (Gilead): DNP+ opposition revoked March 2024; procedural hurdles now loom.
• 3HP (Sanofi): Withdrawn post-opposition 2022; weakened rules threaten preventives.

These highlight oppositions' role in affordability for LMICs relying on Indian generics.

Stakeholder Perspectives: Industry Gains vs. Public Health Concerns

Proponents (Morgan Lewis) hail efficiency attracting FDI, harmonizing with US/EU. MSF, People's Dispatch warn TRIPS-plus via EFTA/UK FTAs erode safeguards, risking Global South access. SpicyIP notes opaque consultations favored trade over input. Balanced: Reforms boost filings (110k FY25), but pharma grants risk health equity.

Broader Implications for Innovation and Economy

Grants rose, filings 61% domestic FY25. Yet, diluted checks may flood weak patents, stifling genuine R&D. India's $58bn pharma eyes $130bn by 2030; generics export $25bn. Risks: Higher drug prices, innovation diverted to tweaks.

International Context and FTA Pressures

Amendments echo EFTA TEPA demands for opposition curbs, Form 27 dilutions. USTR 2024 Special 301 flags India; rules counter perceptions but critics see pro-industry shift.

Future Outlook and Policy Recommendations

Monitor grants, CL attempts. Restore opposition access, mandate detailed Form 27. Leverage research jobs in IP law for balanced reforms. Explore academic career advice for pharma-IP experts.

Photo by Onkarphoto on Unsplash

Conclusion: Safeguarding Public Health Amid Reforms

2024 rules expedite IP but risk health safeguards. India must recalibrate for equitable access. Explore Rate My Professor, higher ed jobs, university jobs, career advice.